Search Medical Condition
Please enter condition
Please choose location

Breast Cancer - HER2 Positive Clinical Trials

A listing of Breast Cancer - HER2 Positive medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (75) clinical trials

The objective of this study is to assess efficacy and safety of radium 223 dichloride in subjects with human epidermal growth factor receptor 2 (HER2) negative hormone receptor positive breast cancer with bone metastases treated with exemestane and everolimus.

Phase

The objective of this study is to assess efficacy and safety of radium-223 dichloride in subjects with human epidermal growth factor receptor 2 negative (HER2 negative) hormone receptor positive breast cancer with bone metastases treated with hormonal treatment background therapy.

Phase

You are being asked to participate in this study because you are a postmenopausal woman with estrogen receptor positive and HER2 negative breast cancer that no longer responds to aromatase inhibitors (anti-estrogen therapy) and has spread in the breast, or to other parts of your body. For patients who receive ...

Phase

You are being asked to take part in this study because you are a woman/man with hormone responsive breast cancer that has already been removed by surgery and you have completed any required chemotherapy or radiation. The purpose of this study is to see whether treatment with everolimus plus hormone ...

Phase

We are studying whether aspirin can prevent breast cancer from coming back or prevent the spread of breast cancer. Studies have linked aspirin with a lower risk of death from cancer.

Phase N/A

The study will include men and pre- and postmenopausal women with HR-positive, HER2- negative high risk EBC after adequate surgical resection, radiotherapy (if indicated), adjuvant or neo-adjuvant chemotherapy, and who are deemed to be eligible for adjuvant ET for at least 60 months of duration.

Phase

The target population for this study is women who are candidates to receive single agent fulvestrant endocrine therapy for metastatic, ER/PR+ and HER2 negative breast cancer. Such patients shall not have received prior treatment with chemotherapy in the locally advanced or metastatic disease setting and must have failed prior systemic ...

Phase